Stryker (SYK) Q3 2024 earnings summary

Executive summary

• Achieved 11.9% year-over-year sales growth in Q3 2024, with organic sales up 11.5% and strong double-digit gains in MedSurg & Neurotechnology and nearly 10% in Orthopaedics & Spine.

• Growth was well-balanced between U.S. and international markets, both rising double digits organically.

• Closed seven acquisitions year-to-date, investing $1.6 billion, including care.ai, NICO Corporation, and Vertos Medical, with $1,598 million upfront and $395 million contingent consideration.

• Adjusted EPS for Q3 was $2.87, up 16.7% from Q3 2023; reported EPS was $2.16.

• Management reaffirmed commitment to margin expansion, product innovation, and acquisitions as growth drivers.

Financial highlights

• Q3 net sales were $5.5 billion, up from $4.9 billion year-over-year; organic sales growth was 11.5%.

• Adjusted EPS was $2.87, a 16.7% increase year-over-year; adjusted net earnings reached $1.1 billion.

• Adjusted gross margin was 64.5%, 20 basis points lower than Q3 2023; reported gross margin was 64.0%.

• Adjusted operating margin was 24.7% of sales, 130 basis points favorable to Q3 2023.

• Year-to-date cash from operations reached $2.3 billion, up $120 million from 2023.

Outlook and guidance

• Full-year 2024 organic sales growth expected at 9.5%-10%, with adjusted EPS of $12.00-$12.10, reflecting a $0.10 negative FX impact.

• Guidance reflects continued product innovation, healthy procedure volumes, and strong commercial execution.

• Targeting 200 basis points of margin expansion by end of 2025, including 100 basis points in 2024.

• Acquisitions in 2024 expected to contribute ~$300 million to 2025 sales.

• Monitoring potential impacts from new global tax laws and regulatory changes.